Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee
Study sponsor: Eupraxia Pharmaceuticals Inc. · EPRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-17Actual
Enrollment · participants318Actual
Source updated2024-06-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.